Threshold Pharmaceuticals Appoints Senior Vice President of Regulatory Affairs
Published: Thursday, April 26, 2012 Last Updated: Thursday, April 26, 2012
Robert Simon will oversee Threshold's regulatory activities related to the development of TH-302, a clinical stage hypoxia-targeted cancer therapeutic currently being evaluated in a variety of cancers.
Full access to this article is for registered users only. Registration is free-of-charge and allows access to all content on our web communities.
Already registered? Then please log in at the top of the page.